close read more

Our 5 therapeutic areas

To discover new treatments that improve patients’ lives, Servier invests an average of 25% of
its sales revenue (excl. generic medicines) in R&D. The Group focuses its research and development
efforts in therapeutic areas where needs are substantial.

    Diabetes

    640 million

    type 2 diabetics
    will be diagnosed
    worldwide in 2040

    7 th

    cause of death
    worldwide

    3

    programs are designed to promote access
    to innovation in the field of diabetes:
    DIRECT, IMIDIA and RHAPSODY

    Servier has been committed for many years to fighting diabetes, a complex and progressive disease that affects 422 million people worldwide.

    Without a profound change in lifestyle and no new treatment, an estimated 642 million people will have diabetes by 2040.

    Servier has always focused on the treatment of type 2 diabetes and its complications. To strengthen its involvement in diabetes complications, such as nonalcoholic steatohepatitis (NASH), Servier signed a partnership with a biotech company based on the West Coast of the United States in 2019. Not well known until recently, NASH is a chronic condition that results from fat accumulation in the liver.

    Linked insights
    More insights